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Personal Experience With 411 Hepatic Resections 
SHUNZABURO IWATSUKI, M.D. and THOMAS E. STARZL, M.D., PH.D. 
Over a 24-year period, 411 partial hepatic resections were per-
formed: 142 right or left trisegmentectomies, 158 lobectomies, 
25 segmentectomies, and 86 local excisions. The operations were 
performed for benign lesions in 182 patients, for primary hepatic 
malignancies in 106, and for hepatic metastases in 123, including 
90 from colorectal cancers. The 30-day (operative) mortality rate 
was 3.2%, and there were an additional six late deaths (1.5%) 
due to hepatic failure caused by the resection. The highest op-
erative mortality rate (6.3%) resulted from the trisegmentecto-
mies, but this Iperely reflected the extent of the disease being 
treated. A mortality rate of8.5% for patients with primary hepatic 
malignancy was associated not only with the extensiveness of 
lesions, but also with cirrhosis in the remaining liver fragment. 
There was no mortality for 123 patients with metastatic disease, 
100 patients with cavernous hemangioma, 22 with liver cell ad-
enoma, 17 with focal nodular hyperplasia, 16 with congenital 
cystic disease, and five with hydatid cysts. Trauma, pre-existing 
iatrogenic injury, and cirrhosis were the only conditions that had 
lethal portent in patients with benign disease. Furthermore, pa-
tients with benign disease who survived operation had minimal 
liability from recurrence of their original disease and none from 
the resection per se. By contrast, tumor recurrence dominated 
the actuarial survival rates for cancer patients, which at 1 and 
5 years were 68.5% and 31.9%, respectively, after resection for 
primary hepatic malignancy, and 84.2% and 29.5%, respectively, 
for hepatic metastases. In this report, the expanding role of par-
tial hepatectomy in the treatment of liver disease was emphasized, 
as well as the need for considering, in some cases, the alternative 
of total hepatectomy and liver replacement. 
A LTHOUGH HEPATIC RESECTION was first carried out over a century ago,l it was not until the pre-
cise lobar and segmental anatomy of the liver 
was appreciated. that controlled anatomic hepatic resection 
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became feasible.2- 7 Almost two more decades ensued be-
fore hepatic resections could be performed safely by many 
surgical specialists interested in this field. 
Our interest in hepatic resection started with the referral 
of patients for liver transplantation whose hepatic lesions 
were believed to be too extensive for subtotal hepatectomy. 
Many such masses could be resected with modifications 
of previously described but uncommonly used operations, 
such as right trisegmentectomy,8,9 or with operations not 
previously performed. 10 Portions of this experience have 
been reported earlier.8- 15 
Methods 
Case Material 
Four hundred eleven patients were treated consecu-
tively at the University of Colorado Health Sciences Cen-
ter (1964-1980) and at the University Health Center of 
Pittsburgh (1981-1987). The case load increased over the 
years (Table 1), 78 resections being carried out in 1987 
alone. 
The patients ranged in age from 11 months to 81 years. 
Twenty-five of the total 411 were younger than 18 years 
of age, and 22 were younger than 12 years of age. The 
182 patients with benign hepatic lesions (Table 2) were 
operated on either because they had the appropriate 
symptoms or because malignancy could not be ruled out. 
Of the 229 malignant lesions, 106 were primary in the 
liver, and 123 were metastatic from various origins 
(Table 2). 
Kinds of Resections 
There were six categories of hepatic resections (Fig. 1): 
right and left trisegmentectomy, right and left lobectomy, 
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TABLE 1. Incidence of Hepatic Resection by 5-year 
Period and Indication 
Number of Benign Primary Secondary 
Years Patients Lesion Malignancy Malignancy 
1964-1970 6 4 2 0 
1971-1975 25 10 10 5 
1976-1980 77 32 17 28 
1980-1985 181 87 43 51 
1986-1987 122 49 34 39 
Total 411 182 106 123 
left lateral segmentectomy, and nonanatomicallocal re-
section. With right trisegmentectomy, the left posterior 
portion of the caudate lobe was removed or retained, de-
pending upon the location of the tumor.s Similarly, with 
left trisegmentectomy, the caudate process alongside the 
retrohepatic vena cava was removed or spared, as dictated 
by the tumor 10cation.1O "Extended" left or right lobec-
tomy, which removed only a portion of the anterior or 
medial segment, respectively, were considered left or right 
lobectomy. 
Nonanatomicallocal excisions were used primarily to 
excise benign tumors or to remove malignant tumors in 
patients with high operative risk factors. Some of these 
so-called local excisions were those of huge lesions and 
were more difficult than anatomic resections (Fig. 2). The 
kinds of hepatic resection used for benign and malignant 
hepatic lesions, as well as the operative mortalities, are 
summarized in Table 3. 
Statistical Analysis 
The results were summarized as of April 1, 1988 with 
a minimum follow-up of 3 months. The survival rates 
were calculated by the method of Kaplan-Meier, and sta-
tistical comparisons were made by the method of Breslow 
and of Mantel-Cox. 
Results 
Operative Mortality 
Operative mortality, defined as death within 1 month 
of the operation, totaled 13 (3.2%) of 411 patients (Table 
3). Nine (6.3%) of 142 patients submitted to right or left 
trisegmentectomy died, as well as three (1.9%) of 158 sub-
mitted to right or left lobectomy. One (0.9%) of the re-
maining 111 patients died after a nonanatomic resection 
(Table 3). 
The mortality rate of patients who received treatment 
of primary hepatic malignancy was 8.5% (Table 3). There 
TABLE 2. Indications for 411 Hepatic Resections 
Benign Hepatic Lesion (182 Patients) Primary Hepatic Malignancy (106 Patients) Secondary Hepatic Malignancy (123 Patients) 
No. of No. of No. of 
Lesion Pts. Malignancy Pts. Malignancy Pts. 
Cavernous Hemangioma 100 Hepatocellular carcinoma 67 Colorectal cancer 90 
(HCC) 
Adenoma 22 Fibrolamellar HCC 12 Intestinal cancer 6 
FNH 17 Nonfibrolamellar 55 Carcinoid 4 
Congenital cyst 16 Cholangiocarcinoma (CHC) 14 Spindle cell sarcoma I 
Polycystic disease 6 Bile duct cancer 6 Leiomyosarcoma 1 
Nonpolycystic disease 10 Carcinoma of hepatic cyst wall 4 Kidney cancer 5 
Trauma 10 Leiomyosarcoma 4 Renal cell cancer 3 
Hydatid cyst 5 Rhabdomyosarcoma 2 Wilm's tumor 2 
Abscess 4 Hepatoblastoma 2 Adrenal cancer 5 
Caroli's Disease 2 Angiosarcoma 1 Adrenocortical carcinoma 4 
Fibroma 1 Adenocarcinoma of gallbladder 1 Neuroblastoma 1 
Leiomyoma 1 Sarcoma, undetermined cell 1 Breast cancer 4 
type 
Mesenchymal Hamartoma Neuroendocrine tumor 1 Adenocarcinoma 2 
Mesenchymoma Adenocarcinoma 1 Comedocarcinoma 1 
Regenerative Nodule Unclassified malignancy 2 Angiosarcoma 1 
Organized Hematoma Gastric leiomyosarcoma 2 
Ovarian adenocarcinoma 2 
Uterus cancer 2 
Squamous cell cancer 1 
Endometrial sarcoma 1 
Melanoma 2 
Glucagonoma, pancreas 1 
Leiomyosarcoma, rectum 1 
Thyroid medullary carcinoma 1 
Ewing's sarcoma 1 
Mesothelioma 1 
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was no mortality in resections for metastatic tumor. Four 
(2.2%) of 182 patients with benign hepatic lesions died. 
Seventeen of the 411 patients had gross cirrhosis; five 
of these patients (29.4%) died. By contrast, the mortality 
rate of patients without gross cirrhosis was eight (2%) of 
394 (p < 0.0 I). Four of the nine deaths after resections 
for primary hepatic malignancy were those of patients 
with obvious cirrhosis. 
Causes of Death 
Deaths Within 1 Month . Details of the 13 operative 
deaths are summarized in Table 4. There were six deaths 
in the operating room, four due to bleeding, one due to 
myocardial infarction, and one due to perforation of the 
atrium by a central venous catheter. Hemorrhage was in-
herently uncontrollable in two of the foregoing cases be-
cause the venous drainage of the remaining hepatic frag-
ment was compromised by the tumor or the trauma that 
had led to the operation. 
Four additional patients died or underwent an attempt 
at liver transplantation during the first week after resection 
(Table 4). Two of these four patients had cirrhosis and 
died of liver failure, whereas a third patient underwent 
liver transplantation 6 days after an unwise attempt at 
right trisegmentectomy had compromised the inferior 
vena cava just above the diaphragm. The death due to 
hepatic failure of one of these patients was particularly 
tragic because the "hepatoma" that had prompted a lo-
bectomy had been a large regenerative nodule (pseudo-
hepatoma). A fourth patient with blunt trauma died sud-
denly I day after operation. The only findings at autopsy 
were cardiomegaly and microscopic fat emboli in the heart 
and the lungs. 
Three other patients died after 19, 20, and 29 days, 
respectively. The first of these patients was referred to us 
with a previously reported dissection of the coeliac axis 
caused by preoperative angiography,9 and the second pa-
tient arrived at our institution with intrahepatic abscesses 
secondary to hepatic artery and hepatic duct injuries dur-
ing cholecystectomy. The third patient died 29 days after 
right trisegmentectomy and left lateral segmental duct re-
construction for Klatskin tumor. 
Another perspective is provided by correlating the data 
in Tables 3 and 4. Only two patients with benign disease 
died, and these were patients with traumatic injuries severe 
enough to require trisegmentectomy, the one patient hav-
ing an iatrogenic liver abscess, and the other having cir-
rhosis and the regenerative nodule of whom was misdi-
agnosed. Of any of the patients who underwent resections, 
the highest mortality rate was that of patients who un-
derwent trisegmentectomy (6.3%). Yet five of the nine 
deaths that occurred with trisegmentectomy resulted from 
the treatment of very extensive primary hepatic malig-
RT TRISEGMENTECTOMY LT TRISEGMENTECTOM Y 
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NON·ANATOMICAL RESECTION LT LATERAL SEGME NTECTOM Y 
fiG . I. Six categories of hepatic resections. 
nancies, and two additional deaths occurred after the 
treatment of massive hepatic trauma. Excluding these 
high-risk cases, the mortality of trisegmentectomy would 
have been less than 2%. 
fiG . 2. Nonanatomicallocal excision of this huge congenital cyst resulted 
in prolonged bile leak, which ceased I month later without surgical in-
tervention . 
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TABLE 3. Extent of Hepatic Resections. Its Indication. and Operative Mortality (411 Patients) 
Right Left Right Left Left Lateral 
Trisegmentectomy Trisegmentectomy Lobectomy Lobectomy Segmentectomy Local Excision Total 
No. of Patients No. of Patients No. of Patients No. of Patients No. of Patients No. of Patients No. of Patients 
(op. death) (op. death) (op. death) (op. death) (op. death) (op. death) (op. death) 
Primary maIignancy 50 (5) 8 (2) 17 (I) 
Hepatocellular 
carcinoma 30 (2) 4 (1) 13 (I) 
Cholangiocarcinoma 5 (1) 3 (1) 2 (0) 
Others IS (2) I (0) 2 (0) 
Secondary 39 (0) 6 (0) 43 (0) 
Colorectal 28 (0) 6 (0) 30 (0) 
Others II (0) 0(0) 13 (0) 
Benign lesion 37 (2) 2 (0) 50 (2) 
Hemangioma 12 (0) I (0) 26 (0) 
Adenoma 8 (0) 1 (0) 8 (0) 
FNH 2 (0) 0(0) 3 (0) 
Congenital Cyst 7 (0) 0(0) 3 (0) 
Trauma 4 (2) 0(0) 4 (0) 
Others 4 (0) 0(0) 6 (2) 
Total 126 (7) 16 (2) 110 (3) 
Delayed Deaths Caused by Resection. Six additional 
patients died more than 1 month after right trisegmen-
tectomy (five examples) or right lobectomy (Table 5) for 
primary malignancy, colon cancer, metastases, and fungal 
abscess. Although some of these patients were able to re-
turn home, hepatic failure was intractable. When these 
six deaths were included, the overall mortality rate in-
creased from 3.2% to 4.6%, and the operative mortality 
rate after trisegmentectomy rose from 6.3% to 9.9%. 
18 (0) 4 (0) 9 (I) 106 (9) 
12 (0) 3 (0) 5 (I) 67 (5) 
3 (0) 0(0) I (0) 14 (2) 
3 (0) I (0) 3 (0) 25 (2) 
16 (0) 12 (0) 7 (0) 123 (0) 
14 (0) 9 (0) 3 (0) 90 (0) 
2 (0) 3 (0) 4 (0) 33 (0) 
14 (0) 9 (0) 70 (0) 182 (4) 
5 (0) 6 (0) 50 (0) 100 (0) 
3 (0) 0(0) 2 (0) 22 (0) 
I (0) I (0) 10 (0) 17 (0) 
2 (0) 0(0) 4 (0) 16 (0) 
I (0) I (0) (0) (0) 10 (2) 
2 (0) I (0) 4 (0) 17 (2) 
48 (0) 25 (0) 86 (I) 411 (13) 
Postoperative Complications 
There were 51 major complications, with some patients 
having more than one (Table 6). Seven (1.7%) of the 411 
patients required re-exploration for postoperative bleed-
ing. Hemorrhage resulted from the cut surface of the liver 
in six patients and from the cystic artery in one patient. 
After hemorrhage was controlled, all but two patients re-
covered without additional complications. The patient 
TABLE 4. Time and Cause of Operative Mortality (Death Within 1 Month) 
Age/Sex Diagnosis Procedure Time of Death Cause of Death 
64/F Cholangiocarcinoma RTS 20 days Hepatic failure 
Celiac axis thrombosis 
22/F Regenerative nodule RL 4 days Postoperative bleeding 
misdiagnosed as HCC Hepatic failure 
50/M HCC in cirrhosis RL o day Perforation of CVP 
Catheter into pericardium, 
cardiac temporade 
63/M HCC in hemochromatosis LTS 7 days Hepatic failure 
281M Abscess after trauma RTS o days Hemorrhage 
77/M HCC in cirrhosis Local o days Myocardial infarction 
55/F Cholangiocarcinoma LTS o days Hemorrhage 
45/M HCC RTS 6 days Hepatic failure 
Transplant on 6th day 
311M Trauma RTS I day Arrythmia due to fat 
emboli? 
52/F Neuroendocrine tumor (?) RTS o day Hemorrhage 
51/M Abscess after cholecystectomy RL 19 days Sepsis, multiple organ 
failure 
36/F HCC in cirrhosis RTS o days Hemorrhage 
62/M Bile duct cancer RTS 29 days Liver failure 
RTS = right trisegmentectomy. Local = nonanatomicallocal excision. 
RL = right lobectomy. HCC = Hepatocellular carcinoma. 
L TS = left trisegmentectomy. 
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who underwent a right lobectomy for pseudohepatoma 
died ofliver failure after re-exploration. A subphrenic ab-
scess developed in another patient who had hemangioma, 
and was drained successfully. Subphrenic abscesses de-
veloped in 24 patients, all after right-sided resection; there 
was a 15.9% incidence of subphrenic abscess after right 
trisegmentectomy. The abscesses were drained surgically 
without delay, usually by a posterior approach through 
the twelfth rib. Three of the 24 patients died of hepatic 
failure after adequate surgical drainage. 
Prolonged bile leaks was observed in 13 patients, but 
closed spontaneously without surgical correction within 
2 months. Bile leaks occurred in 31.3% of the patients 
submitted to left trisegmentectomy, a high complication 
rate that has an anatomic explanation, as previously re-
ported. 10 
After trisegmentectomy, two patients experienced ma-
jor bleeding from stress ulcers in the stomach and duo-
denum. They died of hepatic failure a few days after ulcer 
operations. Other complications, such as deep vein 
thrombosis, myocardial infarction, cerebral vascular ac-
cident, and small bowel obstruction were managed suc-
cessfully (Table 6). 
Follow-up for Benign Lesions 
Cavernous Hemangioma. Giant cavernous heman-
giomas were excised from 25 males and 75 females ranging 
in age from 22 to 77 years, with a mean age of 46.2 years. 
The masses ranged from 4 cm to 41 em, with a mean of 
12 cm in the largest diameter; they were mUltiple in 21 
patients. Focal nodular hyperplasia coexisted in three fe-
male patients and hamartoma in two male patients. In 
eight of the 100 patients, some with and some without 
symptoms, there was a past history of a malignancy, and 
the diagnosis before operation was hepatic metastasis. 
TABLE 5. Time and Cause of Early Death Related 
to Hepatic Resection 
Cause of 
Age/Sex Diagnosis Procedure Time of Death Death 
64/F Angiosarcoma RTS 58 days Hepatic failure 
Thorotrast Pulmonary 
cirrhosis metastasis 
59/M Fungal abscess RTS 32 days Sepsis 
Multiple organ 
failure 
54/M Hepatocellular RTS 45 days Hepatic failure 
carcinoma 
68/M Hepatocellular RTS 33 days Hepatic failure 
carcinoma 
73/M Hepatocellular RL 32 days Hepatic failure 
carcinoma 
71/M Colon cancer RTS 68 days Hepatic failure 
metastasis 
RTS = right trisegmentectomy. 
RL = right lobectomy. 
Forty-five patients complained of pain in the right upper 
quadrant, epigastrium, back, or shoulder girdle. Seventeen 
patients experienced vague but annoying symptoms in-
cluded dysphagia, abdominal fullness, sensation of pres-
sure, early satiety, nausea, vomiting, fatigue, night sweats, 
fever, and weight loss. Eleven patients had anemia with 
a hemoglobin of less than 10 g/dl, three patients had a 
platelet count ofless than l00,OOO/cu mm, and one patient 
carried the diagnosis of primary fibrinolysis for several 
years. Gallbladder disease coexisted in four patients. 
The hemangioma ruptured spontaneously in two pa-
tients, resulting in hemoperitoneum or hemobilia. Eight 
patients experienced hemorrhage after unwise percuta-
neous needle biopsy or open biopsy of vascular lesions. 
In another 15 patients, hemorrhage occurred sponta-
neously into the necrotic center of the giant hemangioma, 
TABLE 6. Postoperative Major Complications in Relation to Extent of Hepatic Resection 
RTS LTS RL 
(n = 126) (n = 16) (n = 110) 
Subphrenic abscess 20 0 3 
Prolonged bile leak 3 5 3 
Postoperative bleeding 3 0 1 
0.1. bleeding 2 0 0 
Deep vein thrombosis I 0 I 
Myocardial infarction 0 0 1 
Cerebrovascular 
accident 0 0 
Small bowel 
obstruction 0 0 
Total 29 5 II 
RTS = right trisegmentectomy 
L TS = left trisegmentectomy. 
RL = right lobectomy. 
LL LLS 
(n = 48) (n = 25) 
0 0 
1 0 
1 0 
0 0 
0 0 
0 0 
0 0 
I 0 
2 0 
LL = left lobectomy. 
LLS = left lateral segmentectomy. 
Local = Nonanatomicallocal excision. 
Local 
(n = 86) 
1 
1 
2 
0 
0 
0 
0 
0 
4 
Total 
(n = 411) 
24 
13 
7 
2 
2 
1 
51 
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FIG . 3. This giant hemangioma with areas of central necrosis sponta-
neously ruptured. Emergency right trisegmentectomy was successfully 
performed. 
and in these patients, preoperative dynamic computerized 
tomography (CT) scan predicted the pathology accurately 
(Fig. 3). Patients with this complication notice a enlarging 
palpable abdominal mass or hepatomegaly, accompanied 
by severe abdominal pain. 
In 13 patients, the hemangiomas were almost or com-
pletely asymptomatic, but in ten of these patients, the 
diagnosis could not be made with certainty, despite an 
extensive work-up. The CT scan of three patients revealed 
central necrosis and blood clot. 
FIG. 4. The multiple liver cell adenoma ruptured spontaneously during 
close observation. Emergency right trisegmentectomy was performed, 
leaving several small adenomas in the left lateral segment. Remaining 
adenomas grew larger, and new adenomas developed. One year after 
hepatic resection, this patient requ ired orthotopic liver transplantation 
to relieve severe pain and other mass-related symptoms. She is doing 
well without recurrence of adenoma 5 years after transplantation. 
Thirteen trisegmentectomies, 31 lobectomies, six lateral 
segmentectomies, and 50 nonanatomic resections were 
used (Table 3). The trisegmentectomies and lobectomies 
were reserved for very large lesions (Fig. 3), but some 
massive hemangiomas could be removed by local excision 
if they were pendulous or had narrow pedicles. 
All 100 patients survived operation and were followed 
for at least several months, after which further visits were 
not encouraged. However, 53 patients were traced for this 
report after 4 months to 14 years (mean of 4.5 years). 
Four patients died of malignancies that had been diag-
nosed before hepatic resection: chronic lymphocytic leu-
kemia, testicular cancer, lung cancer and hypernephroma. 
A fifth patient died from colon cancer that was discovered 
6 years after hepatic resection. None of the surviving pa-
tients developed late complications other than an inci-
sional hernia in one patient. Two of the patients experi-
enced bouts of acute hepatitis with recovery long after 
operation. 
Before resection, 47 of the 53 patients who interviewed 
late had experienced significant symptoms. Forty-one were 
symptom-free, but six patients still had vague abdominal 
complaints that were different from previous ones. Among 
the six patients who were asymptomatic before the op-
eration, two had no postoperative symptoms, and the re-
maining four had died from a previously known malig-
nancy before the follow-up contact. In three patients, small 
hemangiomas were left unexcised, and none have caused 
symptoms subsequently. 
Hepatic Adenoma. The patients ranged in age from 16 
to 60 years, with a mean age of 31.4. Five were male and 
17 were female. Ten of the women had a history of using 
birth control pills or estrogen therapy. Five of the 22 pa-
tients, two men and three women, had multiple adeno-
mas. The size of the tumors ranged from 5 cm to 27 cm, 
with a mean of II cm in the largest diameter. One male 
patient also had a parathyroid adenoma, and one female 
patient had focal nodular hyperplasia. 
Fifteen of the 22 patients had moderate to severe ab-
dominal pain, and four additional patients had vague ab-
dominal complaints. When first seen by us, the adenomas 
had ruptured in six patients with hemoperitoneum (Fig. 
4). Four patients with spontaneous hemorrhage into the 
necrotic center of the adenoma experienced excruciating 
pain. Only three patients were asymptomatic, with their 
solid tumors being found incidentally. These asymptom-
atic adenomas were excised because of an increase in size, 
lack of definitive diagnosis, or because it was believed that 
their presence was reason enough for their removal. 
Lobectomy or trisegmentectomy were used for 20 of 
the 22 resections (Table 3). None ofthe patients died after 
operation, and in 20 cases, follow-ups were available on 
6 months to 17 years, with a mean of 6.5 years. In three 
patients with multiple adenomas that involved all four 
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segments of the liver, some of the lesions were left behind 
after right trisegmentectomy. In each case, either the re-
maining adenomas enlarged or new lesions developed. 
One of these patients died of liver failure 6 years after 
resecti.on. Five years after resection, another patient died 
of cryptococcosis, which was part of her acquired immune 
deficiency syndrome. Another patient who required liver 
transplantation for massive adenoma regrowth I year after 
right trisegmentectomy is alive and well 5 years after liver 
replacement (Fig. 4). No other recurrence is known to us 
at this time. Fifteen patients are free of symptoms after 
resection, and two others still have vague abdominal 
complaints that are different from previous symptoms. 
Focal Nodular Hyperplasia (FNHJ. These 17 female 
patients were 20 to 52 years old, with a mean age of 34.8. 
Thirteen had used birth control pills. Two patients had 
multiple lesions. In 17 patients, there was no coexisting 
benign lesion. The size of the tumors ranged from 4 cm 
to 14 cm, with a mean of 8 cm in the largest diameter. 
Symptoms were milder than those of patients with cav-
ernous hemangioma and with adenoma, and in four pa-
tients, the lesions were found incidentally. One patient 
had had ovarian cancer and another had had a malignant 
histiocytoma of the skin. In no case was the definitive 
ctiagnosis was made before surgery, although the ctiagnosis 
was often suspected. 
Two trisegmentectomies, four lobectomies, one lateral 
segmentectomy, and ten local excisions were performed 
with no deaths occurring. Ten of the 17 patients could be 
contacted in 1988 after a follow-up of 5 months to II 
years, with a mean of 2.5 years. All of the seven patients 
who had had significant symptoms were now symptom-
free, but three patients still had some vague abdominal 
complaints. No recurrence of this lesion is known to us. 
Congenital Hepatic Cysts. Two patients had widespread 
polycystic disease, and four others had multiple cysts that 
were limited to the resected specimen. The remaining ten 
patients had congenital cysts (Table 2). All of the patients 
with large cysts had significant symptoms with a history 
of repeated aspiration of cyst fluid (Fig. 5). Two of the six 
patients with polycystic disease had required intravenous 
(LV.) alimentation and continuous administration of 
narcotics for nutrition and severe pain. Ten of the 16 
patients experienced fever and chills, and four of the pa-
tients had jaundice. 
Seven trisegmentectomies, five lobectomies, and four 
local excisions were performed with no mortality. The 
two patients with severe polycystic liver and kidney disease 
had right trisegmentectomy or right lobectomy, leaving a 
lateral hepatic segment or left lobe that had fewer and 
smaller cysts than the rest of the liver. There was marked 
symptomatic relief for several years, but eventually there 
was cystic enlargement of the fragment and its cysts, which 
returned almost to their original size. 
fiG . 5. This large cyst had been aspirated many times and sclerosed 
several times before excisional therapy. 
In contrast to the recurrences that occur with any pro-
cedure for widespread polycystic disease, none of the pa-
tients whose cyst or cysts could be resected completely 
has ever had subsequent difficulty with complete follow-
ups of 1-15 years. 
Four additional patients who were believed to have be-
nign simple cysts proved instead to have malignant 
changes in the cyst wall. These cases will be considered 
later in this report. 
Other Benign Lesions. The five patients with hydatid 
cysts underwent trisegmentectomy (one example), lobec-
tomy (3 examples), and one local excision. Two of these 
patients proved to be unusually difficult cases, since they 
had been operated upon several times previously. In these 
two patients, the cysts had ruptured into the biliary tract. 
Miscellaneous diagnoses, including trauma, are listed 
in Table 2, and the procedures used are summarized in 
Table 3. Of the 27 patients, four died, three of these four 
deaths being from trauma or prior iatrogenic injury (dis-
cussed earlier). 
Primary Hepatic Malignancy 
The operations performed are summarized in Table 3, 
and the actuarial survivals of patients with primary hepatic 
malignancy are shown graphically in Figures 6 and 7. 
Overall survival rates of 106 patients with primary hepatic 
malignancy were 84.9% at 3 months, 79.1 % at 6 months, 
68.5% at 1 year, 53.9% at 2 years, 45.1 % at 3 years, 37.2% 
at 4 years, and 31 .9% at 5 years after hepatic resection 
(Fig. 6). 
All of the 12 patients who had had hepatic resection 
for fibrolamellar hepatocellular carcinoma are alive, nine 
patients are free of disease 1-15 years after resection, and 
three patients are living with recurrence I, 2, and 7 years 
after resection (Fig. 7). One- to 5-year survival rates of 55 
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FIG. 6. There was no difference in actuarial survival rates between 106 
patients with primary hepatic malignancy and 123 patients with secondary 
hepatic malignancy after hepatic resection. 
patients with nonfibrolamellar hepatocellular carcinoma 
were 76.2%,68.2%,49.0%,36.7%, and 25.0%, respectively, 
and those of 14 patients with cholangiocarcinoma were 
78.6%, 48.6%, 39.8%, 39.8%, and 39.8%, respectively 
(Fig. 7). 
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FIG. 7. The survival rate of patients with fibro1amellar hepatocellular 
carcinoma was higher (p < 0.01) than that of patients with nonfibrola-
mellar hepatocellular carcinoma and with cholangiocarcinoma after he-
patic resection. 
TABLE 7. Fate of 16 Patients with Primary Hepatic Malignancies Who 
Livedfor 5 Years 
Histology Fibrolamellart HCq CHC§ Others" Total 
Number 5 5 3 16 
Trisegmentectomy 5 3 2 13 
Lobectomy 0 2 0 3 
Died > 5 years 0 2 I 0 3 
Time of death (year) 8. 8 6 0 
Living> 5 years 5 3 2 13 
Survival (years) 6,7,' 8,9, 15 7,7, 12 6,* 8 16. 16,16 
* Living with recurrence. 
t Fibrolamellar variant of hepatocellular carcinoma. 
* Nonfibrolamellar hepatocellular carcinoma. 
§ Cholangiocarcinoma. 
II Hepatoblastoma. leiomyosarcoma, rhabdomyosarcoma . 
The four patients with single hepatic cysts that had ma-
lignant degeneration in the cyst wall were treated by tri-
segmentectomies in three cases and local nonanatomical 
resection in one case. The three patients treated with tri-
segmentectomy died of recurrence of squamous cell cancer 
6,10, and 16 months aftertrisegmentectomy. The fourth 
patient, whose solitary cyst contained a small adenocar-
cinoma, is alive and free of tumor 12 months after local 
excision .. 
There were 16 patients who survived more than 5 years 
after hepatic resection for primary hepatic malignancy 
(Table 7). The histologic diagnoses were variable. There 
was an over-representation of trisegmentectomies (13 pa-
tients of 16), and in the remaining three patients, lobec-
tomies were performed. Three of the patients died after 
five years, and two additional patients are living with fi-
brolamellar disease after 6 and 7 years. 
Secondary Hepatic Malignancy 
The overall survival rates of 123 patients with hepatic 
metastasis were 98.3% at 3 months, 95.0% at 6 months, 
84.2% at 1 year, 64.7% at 2 years, 48.9% at 3 years, 38.4% 
at 4 years, and 29.5% at 5 years after hepatic resection 
(Fig. 6). 
The 1- to 5-year survival rates of 90 patients with co-
lorectal carcinoma were 88.1 %, 69.3%, 50.0%, 38.9%, and 
35.8%, respectively (Fig. 3). Those of 33 patients with 
metastases other than colorectal carcinoma were 74.4%, 
53.7%, 45.9%, 37.6%, and 19.9%, respectively (Fig. 8) . 
The difference in survival rates between the two groups 
of patients was not significant. . 
Data from 13 patients who have lived for at least 5 
years after resection are summarized in Table 8. Seven 
are known to be alive after 6-14 years, although one has 
experienced recurrence. Two more were lost to follow-
up, one of whom was free of tumor when, after 8 years, 
he left our care. Long survival was not associated with 
larger resections nearly as often as it was in the primary 
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hepatic malignancies, since only four of these 13 patients 
had been treated with trisegmentectomy. 
Discussion 
This large series of partial hepatectomies was collected 
during a revolutionary period in the history of surgical 
hepatology, a period during which there were three closely 
related basic and clinical developments. First, liver trans-
plantation changed from a seemingly unrealizable dream 
to a highly practical form of therapy. 16, 17 Second, research 
in transplantation stimulated the development of the new 
field of hepatotrophic physiology, which has greatly in-
creased our understanding of regeneration after partial 
hepatectomy. IS Finally, the techniques and expectations 
of subtotal hepatectomy, as well as the care of patients, 
after such procedures were refined and extended-often 
by transplant surgeons who were trying to define the re-
lationship between partial hepatectomy and the new pos-
sibility of total liver excision and replacementI9- 22-were 
remarkably improved. 1,8,IO,23,24 The extent to which liver 
resection has become part of the modem-day armamen-
tarium of oncologists is evident from the plethora of series 
reported during the last 25 years. 14,15,25-33 
As a corollary, attitudes have changed remarkably about 
the utility of partial liver removal. Until approximately 
15 years ago, the mortality that occurred with any of the 
major resections was too great to justify their use if a less 
dangerous, albeit unsatisfactory, alternative was available. 
This point of view can no longer be supported, and in-
dications for hepatic resections have become far less re-
strictive for both malignant and benign disease. This was 
particularly well-illustrated in our series in which 44.3% 
of the procedures were performed for benign conditions. 
It was possible to remove giant hemangiomas from 100 
patients without a single death's occurrence, and to carry 
out 22, 17, and 21 resections for adenomas, FNHs, and 
cystic lesions (including hydatic cysts), respectively, like-
wise without an occurrence of death. And except for two 
victims of extensive trauma, one patient with an abscess 
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patients with colorectal metastasis and 33 patients with other metastases 
after hepatic resection. 
caused by prior iatrogenic injury, and one patient with 
cirrhosis in whom an incorrect diagnosis of hepatoma 
was made, there was no operative mortality in the treat-
ment of benign lesions. 
Because of the remarkable safety of these treatments, 
it would be easy to have the pendulum swing to the over-
use of hepatic resection. One possible stimulus of abuse 
of resection technology might be the increasing numbers 
of hepatic mass lesions that are found incidentally by ad-
vanced imaging methods. Most of these asymptomatic 
lesions are histologically benign, and in past years, would 
have been discovered only at autopsy, if at all. Yet al-
though imaging has allowed patient screening, it has not 
been effective in defining pathognomonic findings of he-
patic lesions other than hemangiomas and cystS.34- 36 Per-
TABLE 8. Fate of 13 Patients with Hepatic Metastases Who Survivedfor More than 5-Years after Hepatectomy 
Leiomyosarcoma Adrenal 
Histology Colorectal Carcinoid of Stomach Neuroblastoma Total 
Number 9 2 I 1 13 
Trisegmentectomy 2 0 I I 4 
Lobectomy 3 I 0 0 4 
Lateral Segmentectomy 4 1 0 0 5 
Died> 5 years 3 1 0 0 4 
Time of death (years) 6,7,8t 8 
Living> 5 years 4 I 1 1 7 
Survival (years) 6,* 7, 8, 14 9 15 15 
Lost at follow-up (years) 6,* 8 2 
* Had recurrence when last seen. t Died with myocardial infarction tumor-free. 
430 IW A TSUKI AND STARZL Ann. Surg .• October 1988 
cutaneous needle biopsy often fails to establish a definitive 
diagnosis because of its limited sampling, and the pro-
cedure can cause serious hemorrhage when unwisely per-
formed for vascular lesions. 
Our approach to incidental hepatic masses that are less 
than 3 cm in diameter has been close observation and 
repeat ultrasonography or CT scan examination if there 
is no reason to be suspicious of malignancy. Any change 
in the imaging characteristics of the mass or increases in 
its size should be a signal for immediate excision. Large 
incidental tumors, with the possible exception of heman-
giomas, usually should be excised. 
A case can be made for watching cavernous heman-
giomas. Spontaneous hemorrhage from these lesions is 
not common.37,38 However, large hemangiomas that are 
completely asymptomatic are uncommon, provided that 
a careful history is taken. Hemangiomas exceeding 10 cm 
in diameter and that have central necrosis can rupture or 
bleed. Two of the 17 patients in this subgroup in our 
series had emergency operations for rupture, and eleven 
others required urgent operations because of an acutely 
enlarging mass with severe pain (Fig. 4). More and more 
frequently, we have come to the conclusion that large size 
alone justifies excision of this type of hemangioma. The 
possibility of an error in diagnosis is one very important 
reason not to be too conservative. Three patients in our 
series who had been believed to have typical imaging 
characteristics of hemangioma before surgery actually had 
malignant tumors; there were two hepatocellular carci-
nomas and one adrenal carcinoma that directly invaded 
the right lobt;~of the liver. 
Arguments 'ffor conservatism in treating adenomas39 
would be harder to sustain. The well-known propensity 
of these lesions to rupture, causing life-threatening hem-
orrhage, was seen in almost half of our 22 patients. Our 
adenoma patient population was heterogenous in that it 
included five males, and several females who had never 
received hormone therapy. FNH, which at one time was 
confused with adenoma,40 could be watched if the diag-
nosis were absolutely certain, since these lesions rarely 
rupture or bleed.38.41 ,42 However, the possibility ofa missed 
diagnosis with either adenoma or FNH-even at insti-
tutions where experienced and skillful pathologists are 
available-can be illustrated by our own experience. One 
of our patients, whose tumor was originally was diagnosed 
as adenoma, developed bone metastases from his hepa-
tocellular carcinoma two years after right hepatic lobec-
tomy. The diagnosis ofFNH was made on frozen section, 
only to have the final diagnosis offibrolamellar hepatoma 
made when the full resected specimen could be studied 
later. Some of our patients have had an adenoma and 
FNH in the same liver. 
The problem of missed diagnosis was tragically high-
lighted in four of our patients who had single hepatic cysts, 
three of whom had been incorrectly diagnosed and op-
erated on elsewhere. In these three patients, the cysts had 
been aspirated, and in two of the patients, the cysts had 
been drained through jejunal Roux limbs. Bloustein and 
Silverberg have provided detailed pathologic analysis on 
one such patients.43 By the time we performed resection, 
the tumors had spread in three of the four patients, who 
died after 6-16 months. The only survivor underwent 
primary local excision and is now tumor-free 12 months 
later. 
Aspiration,44 internal drainage,45 marsupialization,46 
fenestration,47 and sclerotherapy48 have all been recom-
mended for congenital hepatic cysts. These approaches 
are no longer justifiable for the treatment of single or lo-
calized multiple cysts that can be resected so safely. The 
same generalization, with some qualifications, might be 
made about hydatid cystic disease. Although our experi-
ence was limited to five cases only, these patients had had 
multiple previous operations over a period of several years 
at outstanding clinics, in both the United States and 
abroad. Increasingly complex problems had developed, 
such as communication between the dominant cyst and 
the biliary tract and the growth of satellite cysts. Despite 
this, however, it was possible at the end of the therapeutic 
line to excise the cystic disease, although the lobectomies 
were exceptionally difficult. The presence of many adja-
cent cysts, as well as fistulas, between the dominant cyst 
and the biliary tract in the surgical specimen made it ob-
vious that a conservative approach with cystectomy would 
have been futile. 
It is unfair to criticize by today's standards therapeutic 
decisions that were made for the treatment of cystic disease 
of any kind many years ago. This is illustrated by two of 
our own patients with polycystic liver and kidney disease 
who were submitted to right trisegmentectomy and right 
lobectomy in 1979 and 1980, respectively. Both had mas-
sive hepatomegaly, so extreme in one patient that she was 
no longer able to eat and could be sustained by LV. hy-
peralimentation only. Because the islands of solid hepatic 
parenchyma were somewhat better represented in the left 
lateral segment or the left lobe, relief of suffering was 
achieved with the partial hepatectomies. Both women are 
still alive, but both have regrown huge cystic livers and 
may require hepatic transplantation in the near future. If 
confronted with the same problem today that we faced 9 
years ago, hepatic transplantation might be recommended 
as the first, not the last, step, and consideration would be 
given to renal transplantation from the same donor. We 
have already accomplished this in two other patients 
(Fig. 9). 
In management decisions the desirability of examining 
the relationship between subtotal hepatic resection and 
total liver removal and replacement will become even 
more obvious as future strategies to treat patients with 
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primary and secondary malignancies evolve. In our total 
collection of resections for both benign and malignant 
disease, there was a very large percentage of trisegmen-
tectomies. This reflected the advanced state of the pa-
thology. In turn, almost all of the mortality that occurred 
after trisegmentectomy was caused either by the malignant 
disease being too extensive to allow safe trisegmentectomy 
or by there being underlying hepatic disease as an addi-
tional adverse prognostic factor. In some of these patients, 
it was realized too late that the appropriate decision would 
have been liver replacement instead of a futile and lethal 
attempt at trisegmentectomy. 
The results after orthotopic liver transplantation for 
malignant hepatic disease have been discouraging. 19-22 
Although the survival rate for the first half year has been 
very high, late tumor recurrence has plagued these efforts. 
In the past, strong efforts at modern-day adjuvant che-
motherapy, treatment with biologic adjuvants, and irra-
diation have not been systematically tried in liver recip-
ients. Yet liver transplantation can result in the cure of 
hepatic malignancy on more occasions than the isolated 
one that has been reported previously. 19-22 As with resec-
tion, 12 the most favorable lesions for transplantation are 
the fibrolamellar hepatomas, and in addition, epithelioid 
hemangioendothelial sarcomas have had apparent "cures" 
in about a half of the cases.20 Even in highly selected cases 
of metastatic liver disease, significant palliation has been 
accomplished, and there is now also the prospect of long 
survival in a tumor-free state. 17.49 
In the past, we have commented that no surgeon should 
surgically explore a hepatic mass without having the com-
petence to perform all of the major resections, including 
the trisegmentectomies. 50 The day may have already ar-
rived when liver replacement under strictly defined cir-
cumstances should also be part of the obligatory arma-
mentarium. 
Lest these remarks be misunderstood, it may be ap-
propriate to conclude by pointing out that, in addition to 
demonstrating how safely hepatic resection can be per-
formed, our observations have also shown that the real 
key to reliable treatment of malignant disease will be non-
surgical. Although the yield from an enormous amount 
of work was substantial in our patients, tumor recurrence 
was the rule, not the exception. To prevent recurrences, 
host-tumor relationships will have to be changed. This 
possibility has been illustrated by experiences-both re-
cent and long ago-with "lymphomatosis" in liver, stom-
ach, small intestine, large bowel, and thoracic organs of 
transplant recipients. These Epstein-Barr virus-related tu-
mors can necrose completely with discontinuance of im-
munosuppression and re-emergence of host immune re-
sponsiveness. 51 - 53 
Twenty-five years from now, the most important and 
practical application of the resectional techniques may be 
FIG. 9. Polycystic disease of the liver. 
in the treatment of benign disease or for the treatment of 
mechanical complications from necrosis of malignant le-
sions caused by biologic or chemical therapy. 
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As was pointed out, from 1964 to 1970, only six resections were per-
formed. Four were for benign disease and two for malignant disease, 
and this has risen exponentially to 78 resections last year alone. 
In our first report of liver resection in 1961, there were nine cases, 
one with death. These numbers had increased by 1983, at the time of 
the last report from our department by Hillary Thompson, to 138 re-
sections with a 30-day mortality of 10%. 
A word of caution should probably be expressed, however, as we enter 
into this era of "safe hepatic surgery." Care should be exercised to see 
that resection is not overused for lesions that could be treated by lesser 
operations. I think many of us would agree that there was a period 15 
or 20 years ago when formal hepatic lobectomy was overused in the 
management of hepatic trauma and that lesser procedures proved more 
reliable. 
Another subject that is brought up in their discussion pertains to the 
question of when transplantation should be used for some conditions 
(for example, sclerosing cholangitis, Caroli's disease, polycystic disease, 
and possibly ductal carcinoma) that are currently treated largely by lesser 
surgical procedures. The palliative procedures that are now used often 
make subsequent transplantation much more difficult and, in some cases 
involving multiple operations, impossible. 
As transplantation proves more and more reliable and durable, the 
selection of the best method of treatment becomes more difficult. I feel 
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quite confident that this review presented today and the recommendations 
made in the manuscript will help to formulate proper courses of action 
for the future. I know that in dealing with Dr. Busuttil's very active 
transplant program, this question arises not infrequently in some of the 
conditions that I have mentioned. 
OUT compliments once again to the authors for presenting us with the 
facts and figures of hepatic surgery of their monumental work of the past 
23 years. 
DR. MARTIN A. AOSON (Rochester, Minnesota): I am pleased to have 
been asked to discuss this report, but wish that Doctor Iwatsuki had let 
me see the manuscript before last night. The use of six categories of 
resection for management of twelve very different pathologic entities 
cannot be discussed in 3 minutes-and a thoughtful review of such ex-
tensive experience involves more considerations than I was able to think 
through while sleeping overnight. 
Doctor Iwatsuki, I did enjoy your presentation, with its pleasant humor, 
very much; and just as did the acrobatic lady patient shown on your last 
slide, you landed on your feet and landed well. 
This report demonstrates the feasibility of safe major hepatic resections 
and reminds us of how much these men have contributed to the anatomic 
basis of safe resectional surgery of the liver. 
I do agree with most of what the authors have said, but I also believe 
that our views about the role of resectional surgery in the management 
of some malignancies and some benign tumors may differ philosophically. 
My experience involves similar numbers of patients, but differs in two 
significant ways. First, I have used extended resections (particularly left 
trisegmentectomy) less often than the authors have. Second, a lesser 
proportion of resections that I have performed have involved benign 
disease. Instead, of about one third of the trisegmentectomies, such op-
erations comprise about one sixth of my practice; and instead of 45% of 
my resections having been performed for benign disease, only about one 
fourth of the resections I have performed have involved benign disease. 
I believethat these differences relate to my concern about the limi-
tations of anatomic solutions to the problems of cancer that are chiefly 
biological. Also, I have been impressed by the role of the natural history 
of benign disease. 
I am not sure that our attitudes differ so much, and the differences 
may have something to do with patterns of referral. Still, I think there 
is a fundamental difference between what can be done and what should 
be done. Doctor Bahnson observed in his Presidential Address that what 
we don't do may be as important as what we do, and Doctor Longmire 
just referred to the difficulty of decisions that come with technologic 
change. Years ago, Einstein said that perfection of tools and confusion 
of goals are characteristics of our time; and the situation has not become 
much better since he first said this. 
Although I cannot ask many of the questions that I have about each 
specific diesease, there are two questions that I have selected. The first 
regards the role ofleft trisegmentectomy in the management of malignant 
tumors of the liver. The risk of this procedure (even in your hands) is 
12%, and half of the patients with malignancies treated with such resec-
tions have been observed less than 5 years. Therefore, bearing in mind 
the great possibility of limited resectional margins, I wonder about the 
risk-benefit equation. Do you believe that it is truly justified, or are you 
reserving your opinion until you learn more about long-term survival? 
My second question concerns the natural history of benign tumors. I 
think that 90% of cysts, focal nodular hyperplasia, and cavernous hem-
angiomas can be safely observed. Decisions regarding whether or not to 
perform operation are difficult only approximately 5% of the time. The 
question is: which benign tumors can be safely observed? I am concerned 
about the half of your resections performed for focal nodular hyperplasia 
that were very major, and would like to know how such resections can 
be justified. 
I am impressed by your record of safety in the conduct of major hepatic 
resections. However, I do think that progress also involves knowledge 
of the true indications for surgery. I hope that the problems of cancer 
will yield to biological solutions in the future, but even then, we will still 
need to know more about the natural history of benign disease. 
DR. LEON PACHTER (New York, New York): By virtue ofa 3% mor-
tality in 400 cases of hepatic resection, the paper presented by Dr. Iwat-
suki and Dr. Starzl will no doubt be regarded as a classic in the annals 
of hepatic surgery. 
The majority of hepatic resections in the United States are, for the 
most part, performed with preliminary hilar and hepatic vein dissection 
and ligation followed by parenchymal resection. 
At New York University, the institutional experience with this tech-
nique, as performed by Drs. Localio, Ranson, Eng, and Coppa in 45 
patients who had colorectal matastasis to the liver, yielded a 4% mortality, 
not unlike the experience at Pittsburgh. 
(Slide) But in a recent group of 15 additional patients, ten of whom 
underwent surgery for colorectal metastasis and five for primary lesions, 
a different technique was used. This is the method that I have used over 
the past 12 years in 65 patients with severe complex hepatic trauma 
requiring inflow occlusion. As you can see here, this was accomplished 
with a mean cross clamp time of 42 minutes, with a range of 28 to 65 
minutes. Three of the 15 patients were cross clamped for more than I 
hour. The technique consisted of hepatocyte protection by topical hy-
pothermia and steroids, coupled with prolonged inflow occlusion and 
resection by the finger-fracture technique of Professor Linn of Taiwan. 
The mean blood loss here was 100 cc. (Slide) There were no cases of 
hepatic necrosis. Liver function tests all returned to normal at the time 
of discharge, and although there was one abscess, there were no deaths. 
The maximum time that liver can withstand normothermic or hy-
perthermic ischemia is presently unknown, but reports from France by 
Huger and StaTZI as well as from others in the United States clearly prove 
that the 15-20 minutes so frequently cited as the maximum time is 
clearly a myth. 
I would like to ask the authors if they have had any experience with 
normothermic or hyperthermic ischemia for elective hepatic resections. 
I would also like to ask them, what was their mean resection time? What 
was their mean blood loss and what precautions, if any, were used in 
dealing with the cirrhotic liver? 
I enjoyed this paper very much and I feel that the results achieved by 
the authors have set the standard for all of us to emulate. 
DR. WILLIAM V. McDERMOTT, JR. (Boston, Massachusetts): It was 
a pleasure to read this impressive series before the presentation, but until 
I had seen the photographs Dr. Iwatsuki has provided, I had not realized 
how beautifully he had selected the cases. 
I don't believe we can match his series in either volume or quality. 
Over 15 years, our total series of hepatic resections for malignant disease 
involved approximately 200 patients, but I will discuss only two subsets 
that could be compared to the series that Dr. Iwatsuki has just presented. 
The overall mortality of less than 4% is similar for both series. I would 
like to comment further on two categories only: 31 primary hepatocellular 
carcinomas and 76 metachronous cancers from colonic origin. Metastases 
from other primaries are not included. 
Our data and conclusions are very similar to those you have just heard 
in the excellent report of Drs. Iwatsuki and StaTZI. From the group of 
76 patients with metachronous metastases, we can present some infor-
mation that I think emphasizes the relative degree of success of this 
procedure in treating patients with otherwise incurable disease. 
In terms of follow-up, in our group the median survivals were as follows: 
in Duke's B, those living free of disease, there were 25 total cases, and 
in Duke's C, there were 21 cases; the actuarial 5-year survival in the 
Duke's B group was 65%, and that of the Duke's C group was 46%. 
We looked at the disease-free interval to see what effect this might 
have on the prognosis. When the interval was less than I year, there was 
a 56% actuarial death rate with a median survival of 10 months, whereas 
when the interval was greater than 4 years, the actuarial death rate had 
dropped down to 25%, leaving us with an overall actuarial' survival of 
46% for the entire group. The median survival increased steadily with 
the interval to 24 months when the interval were 2-4 years, and to 44 
months when the interval was more than 4 years. 
The number of metastases in our series was significant. Eighty per 
cent of those patients with more than three metastases died of disease 
before 5 years. 
Comparing Dr. [watsuki's series with our own, we mentioned their 
similarity and the mortality. In the primary group, there were 101 primary 
hepatocellular cancers compared with our 31; their secondary group in-
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cluded 118 cases of metachronous cancers compared with 76 in our 
group. 
The actuarial survival rate of our primary group was 57% for 5 years; 
their series recorded an actuarial survival rate of 88% for I year, 62% 
for 3 years, and 43% for 5 years. In the group with secondary metastases, 
65% and 45% of the patients were alive and free of disease at 3 and 5 
years, respectively, in comparison with the figures presented by Dr. Iwat-
suki of 46% at 3 years and 31 % at 5 years. Those are really very excellent 
results if you think of what the disease would otherwise imply. 
Our tentative conclusions are that, in selected cases of primary and 
secondary cancer of the liver, resection is thoroughly justified and is 
indicated by the low mortality rates (less than 5%) and the 5-year actuarial 
survival of 46% in the secondary and 57% in the primary cancers. Also, 
resection for primary cancer in cirrhotics is indicated only in carefully 
selected patients because it is in this particular subset that the heaviest 
mortality will occur and perhaps negate extensive efforts at resection. 
Finally, the best results (46% at 5 years in metastatic cancers from the 
colon) will occur in patients having less than 3 metastases, margins greater 
than I cm, an original primary that was a Duke's B classification, and 
an interval greater than 3 years. 
This does not preclude operating on other patients who do not meet 
these stringent criteria, but I present this criteria only to indicate that 
this is the gold standard. If one deviates, the overall survival will obviously 
drop; nevertheless, with thoughtful selection, this is not an absolutely 
rigid point of departure. 
With respect to chromosomal analyses-that is, ploidy-I do not think 
that it is yet at the stage where this technique can be used in a predictive 
way. 
I certainly enjoyed this extensive series. It was very impressive, and 
the results were superb, as you have seen. 
DR. PAUL H. SUGARBAKER (Atlanta, Georgia): About 3 years ago at 
the NIH, Kevin Hughes and I collected retrospective data on approxi-
mately 850 patients with resected hepatic metastases from large bowel 
cancer. To be eligible for this study, the patient had to survive a potentially 
curative hepatic resection from large bowel cancer. We have the Mayo 
Clinic, Sloan-Kettering, the University of Connecticut, and many other 
groups to thank for our large body of data (850 patients). We analyzed 
the data for prognostic factors and patterns of failure, and then intensively 
studied those patients who survived long-term. 
I was surprised by our data regarding prognostic factors, and some of 
my comments will parallel those of Dr. McDermott. Several factors sig-
nificantly reduced but did not abrogate survival. Patients with multiple 
as opposed to solitary metastases did somewhat worse, but not that much 
worse than the patients with solitary metastases. Positive margin patients 
did more poorly, yet a good number survived. Some patients with ex-
trahepatic disease, either in the lungs or elsewhere in the abdomen, that 
was resected at the time of the removal of hepatic tumor survived long-
term and were disease-free. A short free interval was a relative but not 
absolute contraindication to resection. The only clinical feature that we 
found to be an absolute contraindication to hepatic resection for met-
astatic disease was the presence of the disease in the lymph nodes draining 
the hepatic metastases. The phenomenon I call "mets from mets." 
Therefore I would like to ask our presentor: do you have any absolute 
contraindications to the resection of metastases from the liver? 
My second question comes from my own rather discouraging expe-
rience with either right or left trisegmentectomy in the aged patient. I 
have found that, with the trisegmentectomy procedure, some patients 
(even though their blood loss was just a few cubic centimeters, as noted 
in the operative report) sometimes die ofliver failure. And so my question 
is this: do you have an age cut-off when you are performing a triseg-
mentectomy procedure? 
I have a third question: would you go back a second time to remove 
further hepatic disease? We have anecdotal experience with nine patients 
who had a second hepatic resection. One of them died after surgery of 
a myocardial infarction. Eight are doing well long-term after are-resection 
ofliver metastases months or years after the first hepatic resection. What 
is your position on this? 
DR. JOHN S. NAJARIAN (Minneapolis, Minnesota): I, too, rise to con-
gratulate the authors on an outstanding paper, indeed, probably a seminal 
paper in the area of hepatic resection. In an active hepatic transplant 
program, one is fortunate to see patients like these who may benefit from 
hepatic resection. Trisegmentectomy, as we currently practice it, was 
actually defined by Iwatsuki and StaTZl in the two papers they previously 
published on this technique. 
I have one question concerning a very favorable lesion-namely, the 
metastatic lesion of colonic carcinoma. Certainly the results are out-
standing: from a 30 to 40% 5-year survival, depending on the series you 
see. Have you had an opportunity to take some of these patients who 
have had metastases from a colonic carcinoma that is biJobar, and proceed 
with hepatic transplantation after total hepatectomy? 
It would seem that such patients would be the ideal group for this 
type of therapy. I know you have had some experience in this area. We 
would like to hear what results you have achieved. 
DR. SHUNZABURO IWATSUKI (Closing discussion): First of all I would 
like to thank all of the discussants for their nice comments and for bringing 
up some information that I could not deliver today because of the time 
limitation. 
I would like to answer as many of the questions as I can remember. 
Dr. Najarian asked us if we have done liver transplantation for metastases, 
particularly from the colon. Yes, we have done liver transplantation for 
metastases, but not yet for colonic cancer. We are looking for some good 
candidates with colonic cancer metastases of minimally aggressive bio-
logical behavior. We have not yet found an ideal candidate. However, 
in Europe some cases were treated with liver transplantation, although 
the results are not good. One of the reasons for poor results is that there 
is no effective chemotherapy or biological therapy for colon cancer. 
The second question is from Dr. Sugarbaker. He asked me the absolute 
contraindications for resection. 
Our general approach is that if we can make a clinically disease-free 
status by performing a partial hepatectomy and additional resections of 
lymph nodes, diaphragm, or lung, we do so. I don't believe the term 
"absolute" is quite right. The prognosis is poor if you treat advanced 
stages of the disease. However, as we mentioned, there was no operative 
death from any liver resections for metastases. Therefore, I believe that 
we are justified in approaching metastatic liver diseases with aggressive 
surgery. We do not have any age limit for resectional therapy of metastatic 
tumors. We go back for second resections if the first resection is less than 
trisetectomy, and the lesion can be excised completely by smaller resec-
tions. 
Someone asked me about inflow occlusion with the Pringle maneuver. 
We use the Pringle maneuver for left trisegmentectomy almost routinely. 
The reason for this is that after trisegmentectomy the cut surface is very 
large, and hemostasis is rather difficult. We can cross clamp inflow for 
up to 2-3 hours without any fatal results. However, for small restrictions 
such as right or left lobectomy, it is not necessary to block the inflow. 
In other words, blood loss for lobectomy for metastasis is probably one 
or two units or less. 
(Slide) Answering Dr. Adson's questions, this is an hemangioma that 
we usually see. This is central necrosis, and the patient complained of 
pain and fever. I believe it is wrong to observe this patient without offering 
surgery. Of course, we do not remove hemangiomas or cysts in asymp-
tomatic patients if the diagnosis is certain and there is no reason to 
suspect malignancy. 
(Slide) This is a patient with polycystic liver disease. This patient re-
ceived hyperalimentation because the stomach was compressed and she 
experienced early satiety. She required continuous narcotic therapy for 
pain. 
(Slide) This is a patient with an hepatoma treated by right trisegmen-
tectomy. 
(Slide) This huge region cannot be treated by a left lobectomy alone. 
You can see a part of the right hepatic vein here. In order to obtain a 
tumor-free margin, we had to perform a left trisegmentectomy. 
